AMGN compared with INAB: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

INABIN8BIO, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

INABIN8BIO, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

INAB2 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+11.63%—

Q2 FY26—▲+0.90%—

= impliedAMGN realized, solidINAB realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedspan: AMGN 273d · INAB 91dSource: market data

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

INABIN8BIO, Inc.

0.97▲+16.87%· post 0.97

ClosedNov 6 '26

Mkt cap$10.0MRevenue—Revenue—

Compare

ClosedNov 6 '26

AMGNAmgen Inc

INABIN8BIO, Inc.

460.55▲+0.06%post 460.42

Price

0.97▲+16.87%post 0.97

$249.0B

Mkt cap

$10.0M

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN460.55▲+0.06%vsINAB0.97▲+16.87%ClosedNov 6 '26